We monitored the levels of various cytokines and chemokines, as well as an adhesion molecule and factors related to vascular endothelial damage, in three patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome after bone marrow transplantation. Measurements were done at the onset of this condition and during plasma exchange for treatment. At the onset of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, the levels of interleukin-8, thrombomodulin, and plasminogen activator inhibitor-1 were all markedly increased. A close relationship was observed between improvement in symptoms by plasma exchange and a decrease in interleukin-8 level, suggesting that this chemokine may be related to the development of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome after bone marrow transplantation. Bone Marrow Transplantation (2002) 29, 907-911.
in the complications occurring after BMT. 5 In patients with SIRS, inflammatory cytokines are activated by some stimulus, and vascular endothelial cell damage occurs as a result. We have also previously reported that the cytokine interleukin (IL)-12 may be involved in the occurrence of thrombotic microangiopathy (TMA) after BMT. 6 In the present study, we measured various cytokines and factors related to vascular endothelial cell injury in three BMT patients whose course was complicated by TTP/HUS, in order to investigate the pathogenesis of this condition in relation to cytokines and other factors.
Case reports

Case 1
A 22-year-old woman underwent an unrelated BMT in November 1997 for acute lymphoblastic leukemia in second remission. Conditioning consisted of busulfan (4 mg/kg/day for 2 days), cyclophosphamide (30 mg/kg/day for 2 days), and total body irradiation (3 Gy/day for 4 days). The transfused marrow cell count was 3.6 ϫ 10 8 /kg. Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporin A (CsA), methotrexate, and methylprednisolone according to Chao et al's method. 7 CsA was infused from day Ϫ1 for 24 h, and was kept at a target blood level of 400 to 600 ng/ml until marrow engraftment, after which the dosage was varied depending on the symptoms of GVHD. G-CSF was administered at a dose of 8 g/kg from day 5 to day 19. An ANC Ͼ0.5 ϫ 10 9 /l and a platelet count Ͼ50 ϫ 10 9 /l were achieved on day 13 and day 25, respectively. On day 19, grade 1 acute GVHD of the skin was diagnosed and the dose of CsA was increased. Despite this, grade 3 intestinal GVHD also appeared. Methylprednisolone pulse therapy was started on day 25 and CsA was changed to FK506. From day 30 to day 47, betamethasone suppositories (3.95 mg/day) were administered to treat the intestinal GVHD, which improved. 8 Subsequently, her GVHD was controlled by FK506 and methylprednisolone. On day 35, grade 2 BMT-associated thrombotic microangiopathy was diagnosed acording to the criteria of Zeigler et al. 9 From around day 111, fluctuating neurological symptoms appeared, the creatinine level increased to 1.70 mg/dl, the erythrocyte fragmentation rate increased markedly to 5.1%, and the lactate dehydrogenase (LDH) level also increased markedly to 1350 U/l (normal range 120 to 230). TTP/HUS was diagnosed on the basis of these findings. The dose of FK506 was gradually reduced and plasma exchange was performed. Improvement was noted after plasma exchange, so she was monitored while receiving methylprednisolone alone. However, the TTP/HUS worsened again from around day 130 and plasma exchange was repeated. This time it had no effect and the patient died on day 133.
Case 2
A 39-year-old man underwent unrelated BMT in May 1997 for chronic myelogenous leukemia in accelerated phase. Conditioning was the same as in case 1. The transfused marrow cell count was 2.8 ϫ 10 8 /kg. GVHD prophylaxis was as in case 1. An ANC Ͼ0.5 ϫ 10 9 /l and a platelet count Ͼ50 ϫ 10 9 /l were achieved on day 16 and day 25, respectively. From around day 15, grade 2 acute GVHD of the skin was diagnosed and the dose of methylprednisolone was increased. Grade 2 BMT-related thrombotic microangiopathy also developed on day 35, but resolved spontaneously. He was discharged on day 75, but was subsequently readmitted for treatment of interstitial pneumonia. Because proximal muscle weakness, possibly due to chronic GVHD, occurred around June 1999, he was hospitalized again. He was treated with FK506 at a dose of 0.5 mg/day and predonisolone at a dose of 10 mg/day, which was increased to 30 mg/day. On 3 July the red blood cell count decreased to 1.48 ϫ 10 12 /l with severe fragmentation. The LDH level was 1125 U/l, serum creatinine 5.65 mg/dl, and there was a marked decrease in the platelet count to 78 ϫ 10 9 /l. On the same day, fluctuating disturbances in consciousness level developed. A diagnosis of TTP/HUS was made, and plasma exchange was performed regularly. Although the laboratory parameters improved temporarily, his unconsciousness persisted and he died 23 days later.
Case 3
A 35-year-old woman underwent related BMT on 9 August 1995 for myelodysplastic syndrome (refractory anemia). Conditioning consisted of cyclophosphamide (60 mg/kg/day for 2 days) and total body irradiation (3 Gy/day for 4 days). The transfused marrow cell count was 4.0 ϫ 10 8 /kg GVHD prophylaxis was with CsA and methotrexate. CsA was given according to the regimen used for case 1. An ANC Ͼ0.5 ϫ 10 9 /l and a platelet count Ͼ50 ϫ 10 9 /l were achieved on day 12 and day 114, respectively. From around day 12, acute GVHD (grade 2, skin) occurred, but improved with methylpredonisolone. On day 188, she became febrile, with diarrhea and elevation of liver enzymes. Because GVHD was suspected, she was treated with cyclosporin (250 mg/day) and prednisolone (60 mg/day). On day 202, the LDH increased to 741 IU/l and the serum creatinine to 1.86 mg/dl. There was a concomitant decrease in the red blood cell count to 1860 ϫ 10 4 /l accompanied by red cell fragmentation (4.8%), and a decrease in platelet count to 17 ϫ 10 9 /l. In addition, the patient developed a fluctuating disturbance in consciousness and neurological signs. Consequently, a diagnosis of TTP/HUS was made. Plasma exchange was not instituted and she died of severe infection on day 228.
Materials and methods
Blood sampling and assays
Blood samples for all assays were collected in tubes containing 3.8% citric acid at a ratio of 1:9. After separation by centrifugation at 1500 r.p.m. for 10 min at 4°C, plasma was stored at Ϫ80°C. All parameters were measured before the onset of symptoms and at the time of onset of symptoms. Only laboratory tests that showed abnormal values at onset were repeated subsequently in conjunction with the changes of symptoms and treatment during the clinical course.
Assay of parameters
Levels of the following cytokines and chemokines were investigated: tumor necrosis factor-␣ (TNF-␣), interferon-␥ (IFN-␥), interleukin (IL)-1 ␤, IL-2, IL-2R, IL-6, IL-8, IL-10 and IL-12, as well as intercellular adhesion molecule-1 (ICAM-1). All parameters were measured in duplicate each time using the appropriate ELISA kit (Endogen, Woburn, MA, USA) and the mean values were determined.
Assay of other parameters
The level of plasminogen activator inhibitor type 1 (PAI-1) activity was determined using a commercially available chromogenic assay (Biopool, Ventura, CA, USA) (normal 4-43 ng/ml). Soluble thrombomodulin (TM) was measured by a commercially available sandwich enzyme immunoassay based on a monoclonal antibody (Fuji-rebio Co. Ltd, Tokyo, Japan) (normal р4.5 FU/ml). 10 
Statistical analysis
Statistical analysis was done using the Mann-Whitney U test, and P Ͻ 0.05 was considered to indicate a significant difference.
Results
At the onset of TTP/HUS, the levels of IL-8, IL-10, TM, and PAI-1 were markedly increased compared to the values before the onset in all three patients (Figure 1) , while there were slight increases of TNF-␣ and IL-6. The levels of IL-1 ␤, IL-2, IL-2R, IFN-␥, ICAM-1 and IL-12 showed little change at the onset of TTP/HUS (data not shown). Another 75 patients underwent allogeneic BMT during the same period as the current three patients and cytokines or factors related to vascular endothelial injury were measured in 60 of them. In 35 patients whose post-BMT course was uncomplicated, these parameters were measured more than 100 days after BMT for comparison, because TTP/HUS developed more than 100 days after BMT in the three patients. The levels of each parameter were normal in all 35 patients. In one of the three patients (case 1), the levels of IL-8, IL-10, TM and PAI-1 were determined before and after each of three plasma exchange sessions (Figure 2 ). In case 2, the parameters were determined before and after a 
Figure 2
The time course of IL-8, IL-10, TM and PAI-1 levels in case 1. T-1 was at the onset of TTP/HUS, T-2 was before the first plasma exchange (PE), T-3 was after the first PE, T-4 was before the second PE, T-5 was after the second PE, T-6 was before the third PE, and T-7 was after the third PE. The first PE session improved both the symptoms and laboratory data of TTP/HUS. The second PE session also produced a marked improvement of TTP/HUS. The third PE session achieved minimal improvement. The shadowed areas indicate the respective normal ranges.
Bone Marrow Transplantation single plasma exchange ( Figure 3 ). In case 3, these data were determined following the clinical course without plasma exchange (Figure 4 ). In cases 1-3, only IL-8 showed a marked decrease in conjunction with symptomatic improvement with and without plasma exchange ( Figures 2 and 3) ; the other parameters measured, such as IL-10, TM and PAI-1, showed little change (Figures 2 and  3) . These results suggested a close relationship between IL-8 and the clinical manifestations of TTP/HUS. In addition, activity of the proteolytic enzyme for the large multimers of vWF did not correlate with the symptoms in cases 1 and 2.
Discussion
In recent years, investigations into the pathogenesis of primary TTP have shown that there is an increase of unusually large multimers of von Willebrand factor (vWF) with a high adhesive activity, which results in intravascular platelet aggregation and thus leads to the development of TTP. 11, 12 In contrast, van der Plas et al 4 have reported that the activity of this enzyme was not decreased in patients with TTP after BMT, suggesting that TTP after BMT may be different in nature from TTP occurring in other clinical settings. In fact, although plasma exchange is usually effective for primary TTP, there have been only a few reports of plasma exchange being effective for the treatment of TTP after BMT 13, 14 and most reports have indicated that it was ineffective. These findings form the basis for suggesting a difference in nature between the two types of TTP.
For several years, we have measured cytokines and collected data on vascular endothelial injury in our BMT patients with a complicated course, and we recently reported the possibility that SIRS is involved in the complications of BMT. 5 This also suggests that cytokines and vascular endothelial injury may be involved in the occurrence of TMA or TTP/HUS after BMT. We have already demonstrated the participation of IL-12 in thrombotic microangiopathy 6 after BMT. In the present study, the participation of cytokines and vascular endothelial factors in the development of TTP/HUS was investigated after BMT. In all three patients, we found that the IL-8 level increased sharply immediately after the onset of TTP/HUS, and that it subsequently showed alterations that were related to the changes in symptoms. This finding suggests a close association between IL-8 and the development of TTP/HUS after BMT. IL-8 is one of the molecules that are known as chemokines. It is thought that IL-8 has the ability to induce not only the migration and activation of leukocytes, but also the expression of adhesion molecules such as ICAM-1 on endothelial cells or vascular LAF-1 (CD11a/CD18) and Mac-1(CD11b/CD18) on neutrophils. 15, 16 In our patients, the levels of TM and PAI-1 increased along with the elevation in IL-8 level. This association suggests that an increase in the adhesion of neutrophils to sites of vascular endothelial injury may be closely correlated with the status of TTP/HUS after BMT. Because the IL-8 level changed in association with symptoms in our patients and because TM and PAI-1 both increased when IL-8 was increased, the occurrence of TTP/HUS after BMT may involve a cascade of events causing vascular endothelial damage secondary to the elevation of IL-8. As in previously reported cases, in both cases 1 and 2, the IL-12 level increased transiently during recovery of the white blood cell count and a diagnosis of BMT-TMA was made on day 35. With case 3, BMT-TMA was not diagnosed in the post-BMT course, but a transient increase in IL-12 level was also noted during post-BMT recovery of the white blood cell count. In all three cases, the IL-12 level continued to remain normal or subnormal thereafter, and the IL-8 level was increased at the onset of TTP/HUS (the IL-8 level was not increased during white blood cell count recovery in any one of the three cases). It is unknown whether there was causality between the increase in IL-12 level during the post-BMT white blood cell recovery and the increase in IL-8 at the onset of TTP/HUS. Also, the present study was not conclusive because the number of patients was very small, and further investigation is necessary to collect more data.
